文献速递造血干细胞移植与细胞治疗

Belumosudil治疗既往≥2线治疗失败的慢性GVHD:ROCKstar研究

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
PubMed 文献 · Blood · 2021-01-01

ROCKstar是一项2期随机多中心注册研究,评估Belumosudil 200mg每日一次(n=66)与200mg每日两次(n=66)治疗既往接受2-5线治疗的cGVHD患者。主要终点最佳总缓解率分别为74%(95%CI 62-84)和77%(95%CI 65-87),中位缓解持续时间54周,症状改善率分别为59%和62%,耐受性良好。

要点

  • Belumosudil 200mg每日一次和每日两次治疗cGVHD的ORR分别为74%和77%。
  • 中位DOR为54周,44%受试者持续治疗≥1年。
  • 症状改善率分别为59%和62%,不良反应与cGVHD背景治疗预期一致。

核心结论

  • Belumosudil对既往接受2-5线治疗的cGVHD患者显示出有临床意义的缓解且耐受性良好。

研究设计与样本

  • 2期随机多中心注册研究,纳入既往接受2-5线治疗的cGVHD受试者,Belumosudil 200mg每日一次(n=66)或200mg每日两次(n=66)。

主要发现

  • 200mg每日一次组最佳ORR为74%(95%CI 62-84),每日两次组为77%(95%CI 65-87),各亚组均观察到高缓解率。
  • 所有受累器官均出现完全缓解。
  • 中位DOR为54周,44%受试者持续治疗≥1年。
  • 200mg每日一次组和每日两次组症状改善率分别为59%和62%。

关键数值与推荐

  • 主要终点为最佳总缓解率(ORR)。
  • 同时评估缓解持续时间(DOR)、Lee症状量表评分变化、无失败生存、糖皮质激素减量及总生存。

临床怎么用

  • Belumosudil可作为既往多线治疗失败的cGVHD患者的治疗选择,需关注药物相关不良事件导致的停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2), reduces type 17 and follicular T helper cells via downregulation of STAT3 and enhances regulatory T cells via upregulation of STAT5. Belumosudil may effectively treat patients with chronic graft-versus-host disease (cGVHD), a major cause of morbidity and late nonrelapse mortality after an allogeneic hematopoietic cell transplant. This phase 2 randomized multicenter registration study evaluated belumosudil 200 mg daily (n = 66) and 200 mg twice daily (n = 66) in subjects with cGVHD who had received 2 to 5 prior lines of therapy. The primary end point was best overall response rate (ORR). Duration of response (DOR), changes in Lee Symptom Scale score, failure-free survival, corticosteroid dose reductions, and overall survival were also evaluated. Overall median follow-up was 14 months. The best ORR for belumosudil 200 mg daily and 200 mg twice daily was 74% (95% confidence interval [CI], 62-84) and 77% (95% CI, 65-87), respectively, with high response rates observed in all subgroups. All affected organs demonstrated complete responses. The median DOR was 54 weeks; 44% of subjects have remained on therapy for ≥1 year. Symptom reduction with belumosudil 200 mg daily and 200 mg twice daily was reported in 59% and 62% of subjects, respectively. Adverse events (AEs) were consistent with those expected in patients with cGVHD receiving corticosteroids and other immunosuppressants. Sixteen subjects (12%) discontinued belumosudil because of possible drug-related AEs. Belumosudil, a promising therapy for cGVHD, was well tolerated with clinically meaningful responses. This trial was registered at www.clinicaltrials.gov as #NCT03640481.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021. PMID: 34265047. doi:10.1182/blood.2021012021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。